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Genetics
The frequency of ADPKD is estimated to be between 1
in 500 and 1 in 1,000 life births [1]. Two phenotypically
similar forms of ADPKD are associated with mutations on
chromosomes 16 (PKD1) and 4 (PKD2). Mutations in
these genes encoding the proteins polycystin-1 and -2 lead
to abnormalities in cell proliferation, apoptosis, tubular
basement membranes, and tubular fluid secretion,
ultimately resulting in slowly expanding renal cysts (Fig.
1). This disease is autosomal dominant with virtually
complete penetrance of the abnormal genes. However,
recent information suggests that some patients with
milder disease may have incom-plete penetrance of the
abnormal mutated gene [2]. A great deal of individual
overlap exists in the phenotype between patients with the
PKD1 mutation and the PKD2 mutation. As a group,
however, patients with the PKD1 mutation progress more
rapidly to end-stage renal disease and have a more severe
renal insult compared to those with PKD2 [3], perhaps
because patients with PKD2 form fewer cysts [4].
ADPKD is thought to be an example of a “second hit”
phenomenon. An individual inherits a mutated polycystic
kidney disease gene from one of his or her parents. The
wild-type or normal allele in individual cells may then be
affected by a so-called “second hit” allowing this cell to
proliferate and form individual cysts [5]. No more than 5%
of nephrons are thought to be involved in cystic change,
but the genetic mutation is obviously present in all cells.
Some manifestations of ADPKD, such as intracranial
aneurysms, also persist in families.
Pathophysiology and pathobiology
The polycystin proteins are situated within the cell in
areas involving the primary cilium. Thus, mutated poly-
cystins are an example of a ciliopathy. The cilia’s function
is to transmit mechanosensory signals into the cell
controlling cell growth and proliferation. When the poly-
cystins are mutated, a complex series of events ensues,
leading to growth of individual cells and then to the
formation of a fluid-filled cyst [6,7]. As the cyst gradually
enlarges, it becomes pinched off from the nephron of
origin. Because fluid secretion continues, the result is a
gradually enlarging cystic kidney with an increased
volume. The renal parenchyma may also show abnormali-
ties, but the primary pathophysiologic process of the cystic
kidney is a gradually enlarging kidney with an increase
in renal volume. Recent data have suggested that the pro-
gression of renal disease, the occurrence of hypertension,
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Because autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic
abnormalities seen in today’s medical practice, many internists will likely treat patients affected by this condition.
Genetic abnormalities have been increasingly recognized, and the pathophysiology of the disease is beginning to
be unraveled. Because of advances in imaging technology, surrogate markers for disease progression have
allowed clinical studies of newer therapeutic agents to proceed. In the near future, therapies for this common
genetic disease may be available to either prevent or stabilize the disease course for many affected individuals.
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REVIEWand symptoms of the disease are related to kidney volume
[8,9]. In fact, in most cases, renal volume increases years
before the glomerular filtration rate starts to decrease,
making the glomerular filtration rate or its surrogate serum
creatinine a poor way to follow patients with ADPKD.
Diagnosis
An ADPKD diagnosis is usually made by renal imaging,
and ultrasound is most frequently used. Ultrasound
criteria for diagnosis have been recently published, based
on ultrasound examinations with known ADPKD type
1 and type 2 compared to the ultrasound frequency of
cysts in a normal unaffected population [10]. Thus, the
number of cysts correlated with patient age helps make
the diagnosis. A single negative ultrasound examination
in a young person at risk for ADPKD because of family
history does not necessarily exclude the diagnosis. While
magnetic resonance imaging (MRI) and computed tomo-
graphy scanning are perhaps slightly more sensitive for
detecting cysts, the cost of these procedures is much greater
than ultrasonic examination and less widely available.
At present, ultrasound should be used preferentially
for diagnosis. With modern advances in genetics, the
DNA sequence of individual patients can be determined.
However, these expensive tests are not widely utilized at
the present time, except in unusual cases to confirm a
questionable diagnosis or to exclude a possible organ
donor in a patient with a family history of ADPKD [11]. 
Course and prognosis
Eventually, with ADPKD, all patients develop pro-
gressive involvement of the kidneys. Each patient has his
or her signature rate of cyst growth [8]. In general,
patients with PKD-1 reach end-stage renal disease about
10-15 years earlier than those with the PKD2 mutation.
Note that not all patients who carry this genetic abnor-
mality reach end-stage renal disease and many patients,
particularly those with type 2 disease, die prior to chronic
kidney disease becoming a clinical problem. The renal
volume of a patient as determined by MRI is an important
prognostic marker in an individual patient regarding the
likelihood to progress. These changes in renal volume
have been detected by sophisticated MRI studies, and a
population of patients with slower progression and another
group with faster progression appear to exist [8,9]. All of
the risk factors for progression have not been determined,
but a large renal volume is associated with a decrease in
renal blood flow as indicated by MRI studies, hypertension,
and male gender [9].
Signs and symptoms
Many patients with ADPKD are completely asympto-
matic. A minority of patients will have early clinical
symptomatology such as urinary tract infections, gross
hematuria, or abdominal pain, which brings them to
medical attention. At that point, imaging studies will
confirm the diagnosis. However, the vast majority of
patients have few signs and symptoms and often are
diagnosed because of their positive family history or the
development of hypertension. Hypertension is probably
the most remediable and serious complication of ADPKD
[12]. The new onset of hypertension in a patient at risk
for polycystic kidney disease should prompt aggressive
treatment and diagnostic studies. Patients with hyper-
tension during the course of ADPKD have early and more
severe left ventricular hypertrophy. The pathogenesis of
hypertension in ADPKD is thought to be due to activation
of the renin-angiotensin system (Fig. 2). Thus, medications
that interfere with that system, such as angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers, are the preferred form of therapy. However, the
evidence that these drugs are better than other drugs that
control hypertension to a similar degree are not robust and
the choice of antihypertensive therapy is largely based on
theoretical considerations [13]. Studies examining the
efficacy and the degree to which blood pressure should
be lowered in ADPKD are now under way.
Other symptoms of ADPKD include the occurrence of
abdominal, back, and flank pain. This pain can be severe
in many individuals and require pain management.
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Figure 1. Tubular cell abnormalities in autosomal dominant
polycystic kidney disease. Mutations on chromosome 16 and 4
encoding polycystin-1 and -2 lead to abnormalities in cell
proliferation, apoptosis, tubular basement membranes, and
tubular fluid secretion, ultimately resulting in slowly expanding
renal cysts.
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Nonsteroidal anti-inflammatory agents have renal effects
particularly in patients with an activated reninangiotensin
system and thus are to be avoided. This leaves individuals
with persistent chronic abdominal pain in a therapeutic
dilemma. These patients often benefit from a careful
approach to their symptoms. Pain adjuvants such as anti-
depressants and muscle relaxants, and in rare cases, inter-
ventions designed to reduce cyst volume surgically or
laparoscopically, are often needed. Gross hematuria and
acute abdominal pain may be secondary to rupture of
individual cysts. Usually these are managed conservatively
but in recurrent cases, interventional radiologic procedures
are necessary [14].
Urinary tract infections during the course of ADPKD are
common. When the renal parenchyma and cysts are
involved, these patients can be refractory to the usual
antibiotics necessary to treat urinary tract infections.
Some individual antibiotics are known to penetrate cysts
well, whereas other common antibiotics do not appear in
cyst fluid and urine in sufficient concentrations to eradicate
a parenchymal infection. Antibiotic groups that are pre-
ferred in patients with parenchymal involvement in
ADPKD include trimethoprim-sulfamethoxazole,
floroquinolones, and chloramphenocol [15,16]. Note that
most patients with ADPKD and urinary tract infections
have the usual types of upper and lower urinary tract
infections that can be managed with many antibiotic
agents. Only those infections involving the parenchyma,
which are refractory to therapy, require cyst-penetrating
antibiotics. The possibility exists for patients with
parenchymal infections to be febrile and have a negative
urine culture because not all cysts are in continuity with
the urinary space. A patient with prolonged fever, failure
to thrive, weight loss, and nonspecific gastrointestinal
symptoms should be evaluated for an occult renal
parenchymal infection. Such infections can be localized
with various radiographic procedures but remain a
difficult therapy problem.
Extrarenal manifestation of ADPKD
The most common extrarenal manifestation of ADPKD
is hepatic cystic involvement. Quite often these cysts are
incidental findings and not clinically significant, although
in women, these cysts can enlarge rapidly particularly
under the influence of multiple pregnancies and hormonal
therapy. They then can become the dominant clinical
problem. Although hepatic failure is uncommon, symptoms
related to a massively enlarged cystic liver include loss of
appetite, weight loss, esophageal reflux, and abdominal
discomfort, which interfere with the activities of daily
living. Under these circumstances, specialized care for
reducing hepatic cyst volume may be required to relieve
symptoms. In rare cases, the cystic liver dominates the
clinical picture and renal involvement is less important.
Intracranial aneurysms are perhaps the most severe
extrarenal manifestation of ADPKD, although aneurysms
are present only in approximately 5% of all patients with
ADPKD. Those with a family history of early death due to
stroke or prior ruptured intracranial aneurysms are much
more likely to have these aneurysms. Ruptured aneurysms
depend on the size attained, and most ruptures occur in
aneurysms that are greater than 10 mm in size. Smaller
aneurysms can be managed expectantly, but frequent
surveillance every 1-2 years is probably wise. If an aneurysm
attains a large size, even if patients are asymptomatic,
intervention should be accomplished either with surgery
or with radiographic techniques. The benefit of treatment
is often counterbalanced by the complications of the
procedure, but a ruptured intracranial aneurysm carries a
50% mortality rate.
Other extrarenal manifestations include a propensity to
hernias, abdominal or inguinal, and a very high incidence
of diverticulosis. A patient presenting with acute abdominal
pain poses a complex problem for differential diagnosis in
that ruptured cysts, cyst infection, and acute diverticulitis
can look remarkably similar clinically. Cardiac valvular
disease of the mitral valve and tricuspid valves, namely
prolapses, are more frequent in patients with ADPKD, but
these seldom lead to clinical problems [17,18].
Figure 2. Mechanisms of hypertension in autosomal dominant
polycystic kidney disease (ADPKD). The pathogenesis of hyper-
tension in ADPKD is thought to be due to activation of the
renin-angiotensin system.
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A patient with ADPKD managed by internists should
have careful blood pressure control and control of other
cardiovascular risk factors such as tobacco smoking,
hyperlipidemia, body weight management, and aggressive
control of diabetes if present. Based on natural history
studies involving MRI determinations of annual increases
in cyst volume, therapeutic trials of agents shown to be
beneficial in animal models of cystic disease are anxiously
awaited. Two such agents are the vasopressin 2 receptor
antagonist, tolvaptan, and the mTOR inhibitor, sirolimus.
These drugs interfere with cyst growth in experimental
animal models, and early data suggest they are well
tolerated in humans. Stabilization or a decrease in cyst
volume will be the outcome measure used to gauge thera-
peutic efficacy in these ongoing clinical trials [19]. Other
drugs that interfere with cyst growth pathways exist,
which are being elucidated in basic science laboratories
and are candidates for therapeutic intervention. If these
therapies prove useful, screening of individuals at risk
for ADPKD will become more important because early
initiation of such therapy may prevent the progression to
chronic kidney disease or even end-stage renal failure.
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